The estimated Net Worth of Mervin Smith is at least $827 Tysiąc dollars as of 2 August 2024. Mervin Smith owns over 688 units of iRhythm Technologies Inc stock worth over $775,239 and over the last few years Mervin sold IRTC stock worth over $51,366.
Mervin has made over 1 trades of the iRhythm Technologies Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Mervin sold 688 units of IRTC stock worth $51,366 on 2 August 2024.
The largest trade Mervin's ever made was selling 688 units of iRhythm Technologies Inc stock on 2 August 2024 worth over $51,366. On average, Mervin trades about 344 units every 0 days since 2024. As of 2 August 2024 Mervin still owns at least 10,360 units of iRhythm Technologies Inc stock.
You can see the complete history of Mervin Smith stock trades at the bottom of the page.
Mervin's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES INC., 699 8TH STREET, #600, SAN FRANCISCO, CA, 94103.
Over the last 8 years, insiders at iRhythm Technologies Inc have traded over $124,847,276 worth of iRhythm Technologies Inc stock and bought 150,000 units worth $2,550,000 . The most active insiders traders include Holdings A/S Novo, Vijay K Lathi oraz Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,872,546. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth $96,506.
irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
iRhythm Technologies Inc executives and other stock owners filed with the SEC include: